Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Degludec

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    $ API Ref.Price (USD/KG) : 193,163Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    US FDA staff flags risk of low blood sugar for Novo Nordisk's weekly insulin
    US FDA staff flags risk of low blood sugar for Novo Nordisk's weekly insulin

    23 May 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-flags-risk-low-blood-sugar-novo-nordisks-weekly-insulin-2024-05-22/

    REUTERS
    23 May 2024
    Share Share
    Novo Nordisk to discontinue Levemir insulin in U.S. market
    Novo Nordisk to discontinue Levemir insulin in U.S. market

    09 Nov 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-discontinue-levemir-insulin-us-market-2023-11-08/

    REUTERS
    09 Nov 2023
    Share Share
    Novo's Biologic Xultophy (Degludec, Liraglutide) Receives Approval in the U.S.
    Novo's Biologic Xultophy (Degludec, Liraglutide) Receives Approval in the U.S.

    10 Jul 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208583

    FDA
    10 Jul 2023
    Share Share
    Novo's Biologic Ryzodeg (Insulin aspart & insulin degludec ) Receives Approval in the U.S.
    Novo's Biologic Ryzodeg (Insulin aspart & insulin degludec ) Receives Approval in the U.S.

    06 Oct 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203313

    FDA
    06 Oct 2022
    Share Share
    Novo's insulin degludec:Liraglutide Receives Approval in the U.S.
    Novo's insulin degludec:Liraglutide Receives Approval in the U.S.

    01 Jul 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203314

    FDA
    01 Jul 2022
    Share Share
    Once-weekly insulin icodec shows superior reduction in HbA1c vs insulin degludec
    Once-weekly insulin icodec shows superior reduction in HbA1c vs insulin degludec

    28 Apr 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/04/28/2431662/0/en/Once-weekly-insulin-icodec-demonstrates-superior-reduction-in-HbA1c-vs-insulin-degludec-in-people-with-type-2-diabetes-in-ONWARDS-2-phase-3a-trial.html

    GLOBENEWSWIRE
    28 Apr 2022
    Share Share